KR20190092476A - 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법 - Google Patents

돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법 Download PDF

Info

Publication number
KR20190092476A
KR20190092476A KR1020197019050A KR20197019050A KR20190092476A KR 20190092476 A KR20190092476 A KR 20190092476A KR 1020197019050 A KR1020197019050 A KR 1020197019050A KR 20197019050 A KR20197019050 A KR 20197019050A KR 20190092476 A KR20190092476 A KR 20190092476A
Authority
KR
South Korea
Prior art keywords
compound
mmol
amino
group
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020197019050A
Other languages
English (en)
Korean (ko)
Inventor
팅후 장
지안웨이 체
Original Assignee
이소큐어 바이오사이언스 인코퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이소큐어 바이오사이언스 인코퍼레이티드 filed Critical 이소큐어 바이오사이언스 인코퍼레이티드
Publication of KR20190092476A publication Critical patent/KR20190092476A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197019050A 2016-12-19 2017-12-18 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법 Abandoned KR20190092476A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436328P 2016-12-19 2016-12-19
US62/436,328 2016-12-19
US201762536367P 2017-07-24 2017-07-24
US62/536,367 2017-07-24
PCT/US2017/067050 WO2018118793A1 (en) 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Publications (1)

Publication Number Publication Date
KR20190092476A true KR20190092476A (ko) 2019-08-07

Family

ID=62627122

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197019050A Abandoned KR20190092476A (ko) 2016-12-19 2017-12-18 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법

Country Status (8)

Country Link
US (2) US11149032B2 (https=)
EP (1) EP3555079A4 (https=)
JP (1) JP2020502116A (https=)
KR (1) KR20190092476A (https=)
CN (1) CN110291085B (https=)
AU (1) AU2017379796B2 (https=)
CA (1) CA3047136A1 (https=)
WO (1) WO2018118793A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2814290T3 (es) * 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante
EP3787629A4 (en) 2018-05-02 2022-01-05 Kinnate Biopharma Inc. CYCLINE-DEPENDENT KINASE INHIBITORS
SG11202013175SA (en) * 2018-06-29 2021-01-28 Kinnate Biopharma Inc Inhibitors of cyclin-dependent kinases
CN111825666B (zh) * 2019-04-23 2024-03-08 上海仕谱生物科技有限公司 二聚或多聚体形式的突变型idh抑制剂
TW202227138A (zh) * 2020-09-14 2022-07-16 美商托特斯藥品公司 治療性共軛體
CN120554346A (zh) * 2024-02-28 2025-08-29 中国科学院上海药物研究所 一类噁唑酮取代的嘧啶胺化合物及其制备方法、药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1257546A1 (en) * 2000-02-17 2002-11-20 Amgen Inc. Kinase inhibitors
AR064571A1 (es) * 2006-12-28 2009-04-08 Basf Ag Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.
KR20140069235A (ko) * 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
ES2768694T3 (es) * 2014-09-19 2020-06-23 Forma Therapeutics Inc Composiciones de quinolinona pirimidinas como inhibidores de isocitrato dehidrogenasa mutante
WO2017140758A1 (en) 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
ES2814290T3 (es) * 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante

Also Published As

Publication number Publication date
WO2018118793A1 (en) 2018-06-28
US20210403460A1 (en) 2021-12-30
AU2017379796B2 (en) 2021-10-21
CN110291085A (zh) 2019-09-27
EP3555079A1 (en) 2019-10-23
CA3047136A1 (en) 2018-06-28
CN110291085B (zh) 2023-01-24
AU2017379796A1 (en) 2019-07-04
US20200071309A1 (en) 2020-03-05
JP2020502116A (ja) 2020-01-23
EP3555079A4 (en) 2020-08-19
US11149032B2 (en) 2021-10-19

Similar Documents

Publication Publication Date Title
KR20190092476A (ko) 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법
AU2015205374B2 (en) Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
AU2008241610B2 (en) Novel n- (8-heteroaryltetrahydronaphtalene-2yl) or n- (5- heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain
EP4043466B1 (en) Prc2 inhibitors
KR102699906B1 (ko) 브루톤 티로신 키나제 억제제
AU2005228291A1 (en) Tetrahydronaphthyridine derivatives and a process for preparing the same
KR102678781B1 (ko) Sgk 활성을 조절하기 위한 화합물 및 약학 조성물 및 이의 방법
JP2012532916A (ja) 特に睡眠障害及び薬物中毒の治療に適したスピロアミノ化合物
KR102920599B1 (ko) 항종양 활성을 갖는 화합물 및 이의 용도
KR20210131314A (ko) 헤테로시클릴 화합물, 이를 포함하는 약제학적 조성물, 이의 제조 방법, 및 이의 용도
CA2555800C (en) Piperidinylcarbonyl-pyrrolidines and their use as melanocortin agonists
CN111051309A (zh) 可用作a2a受体拮抗剂的三唑并三嗪衍生物
CA2694359A1 (en) Novel heterocyclic compounds as mglu5 antagonists
AU2017341999B2 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
KR20230146607A (ko) Wee-1 억제제로서 피리미딘 화합물
KR20200067129A (ko) 돌연변이체 이소시트레이트 탈수소효소 억제제 및 그 조성물 및 그 제조방법
CN117412981A (zh) 氧化膦衍生物及其制备方法和应用
CN121794269A (zh) 含二氢嘧啶-2,4(1h,3h)-二酮的多环衍生物及其药物组合物、其制备方法和其用途
WO2026090477A1 (en) Helicase inhibitors and uses thereof
HK40019786A (en) Triazolotriazine derivatives as a2a receptor antagonists
HK1187341B (en) Guanidine compound

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190701

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201110

Comment text: Request for Examination of Application

PC1902 Submission of document of abandonment before decision of registration
SUBM Surrender of laid-open application requested